Introduction {#Sec1}
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The occurrence of cancer therapy-related chronic pain has become more frequent over the past few decades. This is because cancer treatments such as surgery, chemotherapy, hormonal therapy, and radiotherapy, among others, when used individually and in combination, have potential side effects that can lead to severe and persistent pain \[[@CR1]\]. Chemotherapy-induced peripheral neuropathy (CIPN), for example, has become more prevalent as increased numbers of neurotoxic agents have been introduced as treatment for different types of cancer \[[@CR2]\]. Dose reduction or discontinuation of these chemotherapeutic agents might limit any potential curative effects and ultimately reduce the chance of survival. Therefore, CIPN is a common complication associated with several classes of chemotherapeutic agents. These agents include platinum-based compounds (cisplatin, carboplatin, and oxaliplatin), taxanes (paclitaxel and docetaxel), and vinca alkaloids (vincristine and vinblastine). The symptoms of CIPN mostly depend on the involved nerves. The most common symptoms are numbness, pain (shooting, stabbing, burning, tingling, or electric/shock-like pain), loss of feeling, impaired manual dexterity, balance problems, and decreased or absent reflexes \[[@CR3]--[@CR5]\]. These symptoms can seriously impair the patient's quality of life (QoL) and are thus important to address.

Colorectal cancer (CRC) is among the leading causes of cancer-related mortality, and its prevalence has increased in Japan. Oxaliplatin is a third-generation platinum-based cytotoxic agent that is used in the oxaliplatin-based regimen FOLFOX, a standard chemotherapeutic protocol for the treatment of advanced CRC patients with metastasis and in adjuvant settings \[[@CR6]\]. The safety profile of oxaliplatin, for which renal or hematologic toxicity is uncommon, is somewhat different from that of conventional platinum-based compounds \[[@CR4], [@CR7]--[@CR9]\], as the principal and dose-limiting cumulative toxicity associated with oxaliplatin-based chemotherapy is neurotoxicity \[[@CR10]\].

Two distinct forms of oxaliplatin-induced neuropathy have been described in the literature. The first is a unique acute, transient peripheral nerve hyperexcitability syndrome that occurs shortly after the infusion of oxaliplatin. This form of neuropathy usually occurs with low total cumulative doses and can be triggered or exacerbated by exposure to cold stimuli. Patients might experience paresthesia and dysesthesia of the hands and feet, as well as of the larynx and jaw. These symptoms tend to occur within hours of exposure and are reversible over time, especially over the next few hours and days. The symptoms do not generally lead to discontinuation of oxaliplatin-based chemotherapy \[[@CR10]\]. Second, a chronic peripheral sensory neuropathy occurs mainly in distal extremities and presents with symptoms similar to those of cisplatin-induced neuropathy. The development of chronic neuropathy is reported to correlate with the cumulative oxaliplatin dose. Indeed, a loss of sensation, dysesthesia, and even functional impairment can develop progressively after several cycles of oxaliplatin-based therapy. These effects are reversible, but might last for several months and have had a significant impact on the continuation of oxaliplatin-based treatment \[[@CR11]\], as these painful symptoms often disrupt the chemotherapy schedule. Furthermore, patients who are unable to complete a planned therapy program might suffer from chronic discomfort and a decreased QoL \[[@CR12]--[@CR15]\].

CIPN-related pain is predominantly neuropathic, and controlled-release (CR) oxycodone was found to be efficacious and tolerable for the treatment of neuropathic pain in several clinical settings. A meta-analysis of the role of opioids in the treatment of benign neuropathic pain showed that opioids, particularly oxycodone, were more effective than other agents \[[@CR16], [@CR17]\]. A randomized phase II trial showed that the combination of oxycodone and pregabalin was effective and safe for the treatment of neuropathic pain in cancer patients \[[@CR18]\].

The objective of this study was to evaluate the efficacy and tolerability of oxycodone in oxaliplatin-induced peripheral neuropathy (OIPN) and its impact on FOLFOX therapy in cancer patients.

Patients and methods {#Sec2}
====================

Patients {#Sec3}
--------

We retrospectively reviewed the medical records of patients with histologically confirmed CRC between November 2006 and February 2012 at the Toho University Sakura Medical Center (Sakura, Japan). Among the reviewed patients, a total of 64 advanced CRC patients with stage III or IV disease were included in this study. All eligible patients underwent gross resection of the primary CRC (microscopic residual disease or residual marginal involvement was allowed) and subsequently received curative-intent oxaliplatin-based FOLFOX therapy. The key inclusion criteria were as follows: ≥18 years of age, a World Health Organization (WHO) performance status score of 0 or 1, and a life expectancy of ≥6 months. Patients with preexisting peripheral neuropathy or those who were previously exposed to other neurotoxic chemotherapeutic agents were excluded from the study.

All patients received modified FOLFOX6 (mFOLFOX6) therapy. mFOLFOX6 comprises a bolus of 85 mg/m^2^ oxaliplatin, 250 mg/m^2^ leucovorin, and 400 mg/m^2^ 5-fluorouracil (5-FU), followed by a 48-h continuous infusion of 5-FU at 2500 mg/m^2^, given every 2 weeks. Bevacizumab, cetuximab, or panitumumab was administered prior to mFOLFOX6 in 27 cases. On a case-by-case basis, the physician in charge determined whether dose reduction or treatment interruption was appropriate in the instance of a severe toxicity response. Oxaliplatin-based FOLFOX chemotherapy was continued until disease progression (PD), the decision to use alternative therapies, unacceptable toxicities, or patient refusal of further treatment.

Study design {#Sec4}
------------

Patients were divided into two groups. Patients with cancer-related pain who had been administered CR oxycodone during the FOLFOX therapy period were defined as the OXY group. Patients who did not receive CR oxycodone treatment were defined as the non-OXY group. The OXY and non-OXY groups included 29 and 35 patients, respectively. No opioids besides CR oxycodone were administered to the study population before and during FOLFOX therapy. Regarding other analgesics, clonazepam was administered to six patients in the OXY group and two patients in the non-OXY group, and gabapentin was administered to one patient in the non-OXY group. Neurological toxicities were assessed according to the Common Terminology Criteria for Advanced Events (CTCAE) version 3.0 (U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute). The severity of neurological toxicity was evaluated as the worst score in each patient during FOLFOX therapy. A peripheral sensory neuropathy subscale was applied to grade the clinical severity as follows: grade 1, asymptomatic or with a loss of deep tendon reflex or paresthesia (including tingling) that did not interfere with function; grade 2, sensory alterations or paresthesia (including tingling) that interfered with function, but not with activities of daily living (ADL); and grade 3, sensory alterations or paresthesia that interfered with ADL \[[@CR19]\]. Pain intensity was also measured on a numeric rating scale after each cycle of FOLFOX therapy. In this study, we focused on oxaliplatin-induced chronic cumulative neuropathy because this type of neuropathy might result in severe neurologic function disturbances and significantly impact the continuation of oxaliplatin treatment.

Statistical analysis {#Sec5}
--------------------

The study was designed to determine differences between patients in the OXY and non-OXY groups, undergoing oxaliplatin-based FOLFOX therapy. For both treatment groups, the medians and relative frequencies were compared using Welch's *t*-test for two independent samples and the Wilcoxon signed-rank test and Fisher's exact test, respectively. Statistical significance was determined as *P* \< 0.05.

Results {#Sec6}
=======

Baseline characteristics of the eligible patients (Table [1](#Tab1){ref-type="table"}) {#Sec7}
--------------------------------------------------------------------------------------

The demographic and clinicopathological data collected from the medical records of 64 patients are shown in Table [1](#Tab1){ref-type="table"}. The OXY group included 29 patients, and CR oxycodone was administered to five patients with cancer-related pain before starting FOLFOX therapy. The daily CR oxycodone doses at baseline ranged from 10 to 40 mg. Other patients in the OXY group received CR oxycodone after the occurrence of painful peripheral neuropathy. The OXY and non-OXY groups did not significantly differ in age (*P* = 0.2582; Welch's *t*-test) or gender (*P* = 1.0000; Fisher's exact test). The maximum daily CR oxycodone doses were as follows: 160 mg for one patient (3.4 %), 40 mg for two patients (6.9 %), 30 mg for three patients (10.3 %), 20 mg for three patients (10.3 %), 15 mg for two patients (6.9 %), and 10 mg for 18 patients (62.1 %).Table 1Baseline characteristics of eligible patientsNon-OXY group x(*N* = 35)OXY group (*N* = 29)Mean age (range)64.9 (48--76)62.7 (48--75)Gender Male1916 Female1713Stage IIIA10 IIIB42 IIIC72 IV2325Chemotherapy regimen mFOLFOX289 mFOLFOX + bevacizumab718 mFOLFOX + bevacizumab + panitumumab02

CTCAE grading of sensory neuropathy during the study period (Table [2](#Tab2){ref-type="table"}) {#Sec8}
------------------------------------------------------------------------------------------------

As shown in Table [2](#Tab2){ref-type="table"}, all patients (100 %) in the OXY group and 33 patients (94.3 %) in the non-OXY group experienced grade 1 or 2 sensory neuropathy. Grade 3 neurotoxicity was not observed in the OXY group, whereas two patients (5.7 %) in the non-OXY group reported grade 3 sensory neuropathy. Although 14 patients (40 %) in the non-OXY group reported mild pain, these patients did not receive opioid therapy. In contrast, every patient in the OXY group who experienced more than mild pain received CR oxycodone. In the OXY group, pain was generally well controlled by adequate dose titration. Two months after the completion of FOLFOX therapy, the sensory neuropathy worsened from grade 1 to 2 in 1 non-OXY group patient, whereas the sensory neuropathy grades remained stable or improved in the other group patients. In the OXY group, the sensory neuropathy grades improved in every patient. CR oxycodone was discontinued in ten patients (34.5 %) in the OXY group after the completion of FOLFOX therapy.Table 2CTCAE grading of sensory neuropathy during study periodNon-OXY group (*N* = 35)OXY group (*N* = 29)Grade 194Grade 22425Grade 320Grade 400Grade 500

Causes of FOLFOX therapy discontinuation (Table [3](#Tab3){ref-type="table"}) {#Sec9}
-----------------------------------------------------------------------------

FOLFOX therapy was interrupted in some cases. The causes of interruption are listed in Table [3](#Tab3){ref-type="table"}. There were no discontinuations due to peripheral neuropathy in the OXY group. However, for ten patients (28.6 %) in non-OXY group, FOLFOX therapy was terminated because of severe OIPN. Eighteen patients (62.1 %) in the OXY group discontinued FOLFOX therapy because of PD, compared with seven patients (20 %) in the non-OXY group. Other reasons for interrupting FOLFOX therapy were unacceptable toxicities besides peripheral sensory neuropathy, scheduled switching to alternative therapies, or patient refusal of further treatment.Table 3Causes of FOLFOX therapy discontinuationNon-OXY group (*N* = 35)OXY group (*N* = 29)Progression disease (PD)718Peripheral neuropathy100Allergic reaction64Fever or infection32Scheduled therapy change03General debilitation50Myelosuppression20Patient's preference22

Frequencies of FOLFOX cycles and total oxaliplatin doses (Table [4](#Tab4){ref-type="table"}) {#Sec10}
---------------------------------------------------------------------------------------------

We also compared the number of FOLFOX cycles in the OXY and non-OXY groups. Patients in the OXY group received a median of 13 cycles of FOLFOX therapy (range, 6--46 cycles). Patients in the non-OXY group received a median of seven cycles (range, 2--18 cycles). The number of FOLFOX cycles in the OXY group significantly exceeded that in the non-OXY group (*P* \< 0.05; Welch's *t*-test). The median total oxaliplatin doses were 1072.3 mg/m^2^ (range, 408.7--3385.3 mg/m^2^) in the OXY group and 483.0 mg/m^2^ (range, 76.2--1414.1 mg/m^2^) in the non-OXY group. The total administered oxaliplatin dose was also significantly higher in the OXY group than in the non-OXY group (*P* \< 0.05; Welch's *t*-test; Table [4](#Tab4){ref-type="table"}).Table 4Frequency of FOLFOX cycles and total oxaliplatin doseNon-OXY group (*N* = 35)OXY group (*N* = 29)Median of FOLFOX cycles (range)7 (2--18)13 (6--46)\*Median of total oxaliplatin dose (ramge)483.0 mg/m^2^ (76.2-1414.1 mg/m^2^)1072.3 mg/m^2^\* (408.7-3385.3 mg/m^2^)\* *P* \< 0.05

There were no statistically significant differences between the five patients who were administered CR oxycodone before FOLFOX therapy and the other 24 patients in the OXY group with regard to the number of FOLFOX cycles (*P* = 0.6094; Welch's *t*-test) and the total oxaliplatin dose (*P* = 0.5424; Welch's *t*-test; data not shown). There were also no statistically significant differences between the OXY group patients who did or did not receive other analgesics with regard to the number of FOLFOX cycles (*P* = 0.2503; Welch's *t*-test) and the total oxaliplatin dose (*P* = 0.3186; Welch's *t*-test; data not shown).

A total of 15 possible opioid-induced adverse events occurred in ten patients in the OXY group during the FOLFOX therapy period. Constipation was the most common event and occurred in eight patients (27.6 %). Other adverse events included drowsiness (6.7 %), nausea (6.7 %), hallucination (3.4 %), and anorexia (3.4 %). The severity of each adverse event was classified as grade 1, and CR oxycodone was not discontinued in any case because of adverse events.

Discussion {#Sec11}
==========

CIPN treatment remains a challenge for clinicians. A number of protective and treatment approaches that focused on CIPN were investigated in clinical trials. However, evidence for pharmacological therapeutic strategies has not been fully established, and further investigation is required.

Regarding the management of OIPN, current recommendations include patient education, dose modification, the "stop and go" approach, and the use of neuromodulatory agents, particularly intravenous calcium and magnesium (Ca/Mg) infusion. Ca/Mg infusion was widely examined, and a meta-analysis that included four prospective randomized clinical trials and three retrospective clinical trials suggested that Ca/Mg infusion might decrease the incidence of OIPN without reducing chemotherapeutic efficacy \[[@CR20]\]. However, Loprinzi et al. revealed that Ca/Mg infusion did not reduce cumulative OIPN in a recent randomized, placebo-controlled, double-blind trial \[[@CR21]\]. A recent randomized pilot clinical trial also failed to demonstrate a protective effect of vitamin E on acute OIPN \[[@CR22]\]. Several antiepileptic and antidepressant agents, including amitriptyline, gabapentin, and lamotrigine, did not show significant efficacy in this setting \[[@CR23]--[@CR25]\]. Among the serotonin and norepinephrine reuptake inhibitors, venlafaxine exhibited a therapeutic effect on painful OIPN \[[@CR26]\]. In addition, duloxetine significantly reduced CIPN-associated pain intensity in a recent randomized placebo-controlled crossover trial, suggesting the clinical efficacy of duloxetine for OIPN \[[@CR27]\].

The efficacy and tolerability of opioids for CIPN has rarely been investigated. However, despite their differing etiologies, agents used to treat peripheral neuropathic pain might have the potential to exhibit demonstrable efficacies for CIPN \[[@CR28]\]. Given their proven clinical efficacies in treating peripheral neuropathic pain, opioids might be effective for the treatment of painful CIPN. In particular, oxycodone provided significant pain relief from peripheral neuropathic pain caused by post-herpetic neuralgia or diabetic neuropathy \[[@CR29]--[@CR32]\]. CR oxycodone was also shown to be effective for bortezomib-induced peripheral neuropathic pain in multiple myeloma patients \[[@CR33]\]. Furthermore, recent basic studies have demonstrated that the antinociceptive effect of oxycodone was superior to that of morphine in a neuropathic pain mouse model \[[@CR34]\] and that the analgesic profile of oxycodone in a bone cancer pain mouse model with a neuropathic pain-like state was different from those of morphine and fentanyl \[[@CR35]\]. Although the pharmacological mechanism of oxycodone against peripheral neuropathic pain remains unclear, the results of those clinical trials and basic studies suggest that oxycodone could be considered a therapeutic option for CIPN.

We retrospectively investigated the efficacy and tolerability of CR oxycodone for OIPN during FOLFOX therapy in CRC patients. A total of 62.1 % of patients in the OXY group continued FOLFOX therapy until PD. Conversely, only 20 % of patients in the non-OXY group continued FOLFOX therapy until PD. The cumulative oxaliplatin dose was significantly higher in the OXY group than in the non-OXY group. Because patients in the OXY group received a higher cumulative dose of oxaliplatin, they would be expected to present with substantially more severe OIPN than patients in the non-OXY group; however, grade 3 sensory neuropathy only occurred in the non-OXY group. These results suggest that CR oxycodone might prevent or improve the symptoms of OIPN in CRC patients.

This study has several limitations. First, the sample size was small and the study design was observational and retrospective. Second, the severity of OIPN was measured according to the CTCAE grading system. The reliability of the CTCAE scale is controversial, and a recent study revealed that CTCAE scale overestimated the occurrence of motor neuropathy \[[@CR36]\]. Finally, the pain intensity in 23 patients (79.3 %) in the OXY group remained mild during the study period, and thus, it was difficult to evaluate the analgesic effects of CR oxycodone on OIPN. Therefore, the continuation of oxaliplatin administration was worth evaluating to confirm the therapeutic efficacy and tolerability of CR oxycodone in patients with OIPN.

Conclusion {#Sec12}
==========

In conclusion, we demonstrated that patients who were administered CR oxycodone received significantly more cycles of FOLFOX therapy and a higher cumulative oxaliplatin dose than did patients who were not administered CR oxycodone. Although this study had several limitations, the results suggest that CR oxycodone can attenuate OIPN and extend FOLFOX therapy in CRC patients.
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